Anthera Pharmaceuticals, Inc. (ANTH) Interim Phase 2b Results Prove Consistent with Previous Studies for Lupus Drug
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs for the treatment of serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study to evaluate the therapeutic benefit of blisibimod injections in patients with lupus. The study enrolled 547 patients in 11 countries and 72 clinical sites around the world to test the efficacy, safety and tolerability of blisibimod. Consistent with previous clinical studies, the on-going PEARL-SC study indicates that weekly and monthly doses of blisibimod significantly reduced B-cells, data which is of value because elevations in these cells have been associated with…